<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376036</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGD010-01</org_study_id>
    <nct_id>NCT02376036</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of MGD010 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MGD010, a CD32B x CD79B Dual Affinity Re-Targeting (DARTÂ®) Bi-specific Antibody-Based Molecule, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010
      intravenous (IV) infusion in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability and PK of MGD010, a CD32B x
      CD79B DART bi-specific antibody-based molecule. This study will be conducted as a
      double-blind, randomized, placebo controlled, single ascending dose study among healthy
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability as assessed by AEs and SAEs</measure>
    <time_frame>up to Day 57</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration (pharmacokinetics) of MGD010</measure>
    <time_frame>up to Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MGD010 anti-drug antibodies (ADA)</measure>
    <time_frame>up to Day 57</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>MGD010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive MGD010 through IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo through IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MGD010 and HepA vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive MGD010 through IV infusion and HepA vaccine through an IM injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and HepA vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo through IV infusion and HepA vaccine through an IM injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGD010</intervention_name>
    <description>MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.</description>
    <arm_group_label>MGD010</arm_group_label>
    <arm_group_label>MGD010 and HepA vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo and HepA vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine</intervention_name>
    <description>Hepatitis A vaccine, inactivated</description>
    <arm_group_label>MGD010 and HepA vaccine</arm_group_label>
    <arm_group_label>Placebo and HepA vaccine</arm_group_label>
    <other_name>Vaqta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 50 years of age

          -  Body mass index (BMI) of 18 to 30 kg/m2, inclusive

        Exclusion Criteria:

          -  Women of child-bearing potential;

          -  Women who are pregnant or breast-feeding

          -  Any significant acute or chronic medical illness

          -  Any major surgery within 4 weeks of study drug administration

          -  Active or latent tuberculosis (TB)

          -  Active or latent Hepatitis B, Hepatitis C or HIV infection

          -  History of allergy to monoclonal antibodies, any significant drug allergy (such as
             anaphylaxis), or hypersensitivity to any components of the test or reference
             investigational product formulation.

          -  Evidence of organ dysfunction or any clinically significant deviation from normal

          -  Vaccination with any live vaccine, or use of any prescription drugs, within 4 weeks of
             study drug administration

          -  Known history of infection or exposure to Hepatitis A virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sadhna Shankar, MD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL Baltimore Early Phase Clinical Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Normal healthy volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

